PARP1

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

Retrieved on: 
Monday, April 8, 2024
PARP1, Chem, MDA, Drug, Patient, Cancer, IND, Abstract, AACR, Survivor, DRF, Clinical trial, PARP, MOA, Xenotransplantation, Safety, Biology, San Diego Convention Center, Drug discovery, Medicine, Annual general meeting, PCC, Pharmaceutical industry

"After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.

Key Points: 
  • "After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.
  • Laekna will continue our internal effort of discovery novel drug candidates to provide more options for patients."
  • The company has internally discovered 14 drug candidates, among which seven have been optimized and advanced to PCC (pre-clinical candidate) stage.
  • The Annual Meeting of AACR is set for April 05 to 10, 2024 at the San Diego Convention Center, California, USA.

Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors

Retrieved on: 
Monday, March 11, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pharmacology, PARP1, Senior, HRD, Medicine, University, CNS, Patient, MD Anderson Cancer Center, PARP, Therapy, Cancer, Safety, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.
  • SNV1521 is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.
  • In preclinical models, selective PARP1 targeting has been shown to improve both the efficacy and safety of the class.
  • “Dosing of the first patient in the SNV1521 Phase I trial is a key milestone as Synnovation transitions from a preclinical to clinical stage biotech company.

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
Wednesday, January 24, 2024
Pharmaceutical, Health, Oncology, Other Health, Entrepreneurship, Vitiligo, Patient, Incyte, Therapy, Rheumatoid arthritis, JAK, Third Rock Ventures, Molecular biology, Pharmacology, Cancer, Medicine, Drug discovery, FGFR, Cholangiocarcinoma, Ruxolitinib, Non-small-cell lung cancer, COVID-19, Atopic dermatitis, PARP1, FDA, Polycythemia, Eli Lilly and Company, Medicinal chemistry, Drug, EVP, GPH, CNS, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Patient, TLR 7, Conference, Protein, Drug discovery, Food, PARP1, WRN, FDA, TLR, DNA, Therapy, Cancer, Cellular, Eikon, PARP, Toxicity, Safety, Pharmaceutical industry

“Eikon has made enormous progress in the development of advanced imaging tools that aid the discovery of important new therapeutics.

Key Points: 
  • “Eikon has made enormous progress in the development of advanced imaging tools that aid the discovery of important new therapeutics.
  • This program is led by Eikon with its collaboration partner, Impact Therapeutics, which is responsible for trial oversight in greater China.
  • Eikon Systems Business Unit Established: Eikon has developed a suite of instruments that permits detailed, automated characterization of protein motion in living cells.
  • An archived recording of Eikon’s presentation at the J.P. Morgan Healthcare Conference can be accessed at: www.EikonTx.com/#news .

Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Retrieved on: 
Monday, October 30, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, PARP1, PARP, DDR, ATM, ADP, Health care, Research and development, Merck, Exercise, Multimedia, Development, ADC, Partnership, Jiangsu Hengrui Medicine, Cancer, Merck Group, ATR, Patient, DNA, Fine chemical, Pharmaceutical industry

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).

Key Points: 
  • Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).
  • The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167.
  • In addition, Merck KGaA, Darmstadt, Germany, has the option to co-promote both assets in China.
  • All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website.

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Retrieved on: 
Monday, October 30, 2023
Health, Science, Pharmaceutical, Research, Oncology, PARP1, PARP, DDR, ATM, ADP, Health care, Research and development, Exercise, Multimedia, Development, ADC, Partnership, Jiangsu Hengrui Medicine, Cancer, ATR, Patient, DNA, Fine chemical, Pharmaceutical industry, Merck

Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).

Key Points: 
  • Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).
  • The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167.
  • Hengrui will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck.
  • All Merck press releases are distributed by e-mail at the same time they become available on the Merck website.

Hengrui Pharma Partners with Merck KGaA, Darmstadt, Germany, to Advance Innovative Cancer Therapies

Retrieved on: 
Monday, October 30, 2023
Science, PARP1, Technology transfer, ADP, Health care, Merck, Development, DNA, ADC, Partnership, Jiangsu Hengrui Medicine, Cancer, Merck Group, Patient, PARP, Pharmaceutical industry

The agreement includes an option to an exclusive license for its innovative Claudin-18.2 antibody drug conjugate (ADC) SHR-A1904.

Key Points: 
  • The agreement includes an option to an exclusive license for its innovative Claudin-18.2 antibody drug conjugate (ADC) SHR-A1904.
  • "Given the high unmet need in oncology, we are excited to work closely with Merck KGaA, Darmstadt, Germany, to bring Hengrui's innovations to cancer patients worldwide," said Frank Jiang, board member and Chief Strategy Officer of Hengrui Pharma.
  • "Partnering with Merck KGaA, Darmstadt, Germany, on our PARP franchise is an important milestone on Hengrui's globalization journey.
  • Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Hengrui Pharma with an upfront payment of €160 million.

Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, S.P. Tre Penne, Temozolomide, Medicine, Merck Group, PARP1, NMS, Glioblastoma, Patient, Conference, Pharmaceutical industry

Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.

Key Points: 
  • Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.
  • The PARPA Phase 1 studies, PARPA-293-001 and PARPA-293-002 are evaluating NMS-03305293 (NMS-293), an oral, brain-penetrant PARP-1 selective inhibitor as single agent or in combination with temozolomide, in relapsed/refractory selected solid tumor types (PARPA-293-001) or patients with High-grade gliomas (PARPA-293-002, including glioblastoma).
  • On September 14, 2022, NMS Group entered into a worldwide option agreement with Merck KGaA, Darmstadt, Germany for the development and commercialization of NMS-293.
  • Details for the plenary and poster presentations are as follows:
    Title: Initial Results from 2 Phase I Studies of NMS-03305293, a Selective PARP1 Inhibitor

Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress

Retrieved on: 
Monday, September 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Partnership, Therapy, Impact, Food, PARP2, WRN, PARP1, EDT, Trial of the century, Science, Data analysis, Patient, Automation, Machine learning, TLR 7, Engineering, Eikon, Drug discovery, Morgan, AI, TLR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, VCP, Antiandrogen, Pharmaceutical industry, IND

“Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.

Key Points: 
  • “Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.
  • “Our advanced analytical tools have enabled Eikon to capitalize on near-term opportunities to bring new medicines to patients.
  • Eikon believes that adverse experiences associated with BDB001 treatment are manageable using Eikon’s proposed clinical dosing regimen.
  • Eikon anticipates initiating Phase 1 clinical studies of IMP1734 in the United States and other jurisdictions in the fourth quarter.

Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline

Retrieved on: 
Thursday, June 1, 2023
Other Health, Pharmaceutical, Research, Oncology, Software, Finance, Hospitals, Genetics, Data Management, Professional Services, Science, Technology, Clinical Trials, Cardiology, General Health, FDA, Biotechnology, Health, Molecule, DSM-IV codes, DNA, Partnership, Therapy, General Grievous, Chromatin, Neurodegenerative disease, Cancer, PARP1, SMT, Protein, Acquisition, Patient, Engineering, Single-molecule experiment, Vaccine, Pharmaceutical industry, Eikon, IND

Lastly, Eikon has acquired a suite of preclinical assets from Cleave Therapeutics that address targets involved in protein homeostasis, DNA damage repair and chromatin remodeling, areas that have importance in cancer and in neurodegenerative disease.

Key Points: 
  • Lastly, Eikon has acquired a suite of preclinical assets from Cleave Therapeutics that address targets involved in protein homeostasis, DNA damage repair and chromatin remodeling, areas that have importance in cancer and in neurodegenerative disease.
  • “With the acquisition of these very different clinical assets, Eikon has taken an important step in building a diverse portfolio, at different stages of the development cycle, which address significant unmet medical needs.
  • As part of its agreement with Impact Therapeutics, Eikon will work to bring the IND-ready asset IMP1734, a highly selective PARP1 inhibitor, into clinical development.
  • Impact CEO Sui Xiong Cai, Ph.D., said, “The Eikon team brings years of experience in oncology to the development of these important assets.